Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic

Setara Biosciences’ lead program is a possible remedy for the uncommon neuromuscular dysfunction Charcot-Marie-Tooth illness sort 2C and the prevalent situation overactive bladder. This small molecule got here from Actio Biosciences, which was not too long ago acquired by Jazz Prescription drugs.

The submit Uncommon Illness Biotech Setara Begins Out With $90M and a Lead Drug within the Clinic appeared first on MedCity Information.

Source link